HDx therapy delivers meaningful and relevant innovation for dialysis patients.
While HDx therapy may offer the potential to improve access to care and to help improve the effectiveness and quality of care, HDx therapy may simultaneously offer dialysis service providers and healthcare systems alike the opportunity to reduce the total cost of care.1,2
Importance of Economics
A reduction in hospitalization and medication usage, may significantly reduce the total cost of care to a Payer and/or Provider.
Primary clinical studies illuminate the benefits of HDx therapy enabled by Theranova
Bunch A et al. Medium cut-off dialyzers in a large population of hemodialysis patients in Colombia: COREXH Registry.
Hospitalization length of stay may be reduced when prescribing HDx therapy enabled by Theranova compared to conventional hemodialysis.3
Ariza JG et al. An initial evaluation of expanded hemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia.
This analysis shows that HDx therapy statistically and significantly reduces hospitalization days and lowers doses of medications (including those used in-center), in a real-world setting over a period of two years.1
Blackowicz MJ et al. Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States.
In this post-hoc analysis of a randomized clinical trial, the HDx therapy with Theranova dialyzer was associated with lower healthcare costs than standard high-flux HD. Theranova is associated with a reduced hospitalization rate per patient year and is expected to be a cost-saving therapy, based on this significant reduction in hospitalization events.2
Molano AP et al. Medium Cut-Off Versus High-Flux Hemodialysis Membranes and Clinical Outcomes: A Cohort Study Using Inverse Probability Treatment Weighting.
This cohort study showed that patients treated with MCO membranes had lower rates of hospitalization and cardiovascular events compared with patients treated with HF membranes. These data support the hypothesis that increased clearance of pro-inflammatory middle-molecules could reduce the occurrence of chronic inflammation, atherosclerosis, structural heart disease and immunodeficiency.4
Provide Expanded Hemodialysis. Retain HD Simplicity.
Hear from patients, nephrologists, and nurses alike share their experience prescribing HDx. Be reassured by the pioneering commitment of Baxter to dialysis patients the world over and learn how Theranova dialyzers are made.
HDx Compendium of Studies
On-going research and clinical reporting are an integral part of the HDx journey. Explore the expanding evidence related to HDx enabled by Theranova that nephrologists around the world continue to generate.
HDx Therapy Brochure
Here you can find the HDx therapy brochure with more information about prescribing HDx for your hemodialysis patients.
HDx Therapy Specification Sheets
Here you can find the detailed profiles of Theranova dialyzers.
Important Safety Information
Theranova dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis.
*Do not use Theranova dialyzers in HDF or HF mode.
For safe and proper use of this device, please refer to Instructions for Use.